Outlook Therapeutics Plans $55M Offering at $0.99 to Fund LYTENAVA Launch
OTLK has more than doubled off its 52-week low of $0.161 on elevated volume (4.2× avg).
Summary
Outlook Therapeutics is raising about $55M through an underwritten offering of ~55.6M shares with warrants at $0.99 per share, with a 30-day option for ~8.3M more shares. The offering closed August 14, 2026. This follows the July 24 FDA approval of LYTENAVA for wet AMD, which transformed the company into a commercial-stage biotech. The financing is highly dilutive at roughly 40% of the current market cap, but it funds the commercial launch and payer work for LYTENAVA. The company had only $11.2M in cash as of August 12 and a going concern warning, so this raise is critical for near-term operations. Watch for initial LYTENAVA sales figures in the next quarterly report.
At the time of this announcement, OTLK was trading at $0.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $141.4M. The 52-week trading range was $0.16 to $3.39. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.